Mounjaro is prescribed by an endocrinologist for adult patients for the following purposes: 🔹 Type 2 Diabetes Mellitus: To improve glycemic control as monotherapy or as part of combination treatment (in addition to diet and exercise). 🔹 Weight Management (off-label/at physician's discretion): For weight reduction in patients with obesity or overweight in the presence of comorbidities (hypertension, dyslipidemia).

Dosage and administration

Sales Form: 1 KwikPen injector containing 2.4 ml of solution. The pen is designed for 4 injections of 2.5 mg each.⚠️ INSTRUCTIONS FOR USE: Dosage Regimen: The starting dose is 2.5 mg once weekly. This dosage is intended for body adaptation and is not therapeutic for sugar control. After 4 weeks, the dose is usually increased to 5 mg. Method of Administration: Subcutaneous injection into the abdomen, thigh, or upper arm. The injection site should be rotated each week. Usage Rules: The drug is administered on any day of the week, regardless of meals. Before the first use, be sure to read the instructions for activating the multi-dose KwikPen. Storage: Strictly in the refrigerator at 2°C–8°C. Do not freeze! After the first use, the pen can be stored at room temperature (up to 30°C) for no more than 21 days.

⛔ Medullary Thyroid Carcinoma: Personal or family history of this disease. ⛔ MEN 2: Multiple Endocrine Neoplasia syndrome type 2. ⛔ Pregnancy and Lactation: The drug is not recommended. When planning a pregnancy, use should be discontinued 1-2 months in advance. ⛔ Type 1 Diabetes: The drug is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis. Severe gastrointestinal diseases (e.g., severe gastroparesis).

Side effects most often appear at the beginning of treatment and diminish as the body adjusts: 🤢 GI Tract (very common): Nausea, diarrhea, vomiting, constipation, abdominal pain, heartburn. 🍽️ Metabolism: Significant decrease in appetite, risk of hypoglycemia (especially when combined with insulin or sulfonylureas). 🏃♂️ General: Weakness, increased fatigue, dizziness. 💉 Local: Redness or itching at the injection site. ⚠️ Rare but serious: Pancreatitis, gallbladder problems, kidney failure (against the background of severe dehydration during vomiting).

Mounjaro KwikPen 2.5 — Tirzepatide 2.5 mg, 1 pcs, Eli Lilly

100% original product

Active ingredient

Tirzepatide

Storage temperature

Cold chain · Storage +2…+8 °C

Shipped in a thermal box with cold packs

Manufacturer

Eli Lilly

Dosage

2.5 mg

Dosage form Prefilled pen

Pens per pack 1

Mounjaro KwikPen 2.5 — Tirzepatide 2.5 mg (1 Pen / 4 Doses) Cold chain · Storage +2…+8 °C

Name: Mounjaro KwikPen 2.5
Brand: Eli Lilly
SKU: PROD-267
Price: 12829 UAH
Availability: OutOfStock

12829₴ ~~14393₴~~ -11% Out of stock

Cold chain Storage +2…+8 °C

This medicine requires temperature control. We pack it in a thermal box with cold packs for safe delivery.

Please return the thermal box with cold packs after delivery. An additional charge applies only if you wish to keep the box.

Mounjaro KwikPen 2.5 mg (Tirzepatide) is an innovative, first-in-class dual-action medication designed for blood sugar control and weight management. Tirzepatide acts as a receptor agonist for two hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This combination allows for more effective reduction of glycated hemoglobin levels, slows gastric emptying, and significantly reduces appetite.

Manufacturer: Eli Lilly. Mounjaro in the KwikPen format is a multi-dose pre-filled pen that ensures convenience and precision of administration. It is an original drug that has undergone extensive clinical trials (the SURPASS program), confirming its superiority over many existing therapies for type 2 diabetes and obesity.

Key Features:

✅ Dual Mechanism: Action on both GIP and GLP-1 receptors provides a synergistic effect in weight loss and metabolic normalization.
✅ KwikPen Format: One pen contains 4 doses of the drug, which is designed for a full one-month course of initial therapy.
✅ Cardioprotective Effect: Positively affects blood pressure and lipid profiles, reducing the risk of cardiovascular complications.

Mounjaro is prescribed by an endocrinologist for adult patients for the following purposes:

🔹 Type 2 Diabetes Mellitus: To improve glycemic control as monotherapy or as part of combination treatment (in addition to diet and exercise).
🔹 Weight Management (off-label/at physician's discretion): For weight reduction in patients with obesity or overweight in the presence of comorbidities (hypertension, dyslipidemia).

Sales Form: 1 KwikPen injector containing 2.4 ml of solution. The pen is designed for 4 injections of 2.5 mg each.

⚠️ INSTRUCTIONS FOR USE:

Dosage Regimen: The starting dose is 2.5 mg once weekly. This dosage is intended for body adaptation and is not therapeutic for sugar control. After 4 weeks, the dose is usually increased to 5 mg.
Method of Administration: Subcutaneous injection into the abdomen, thigh, or upper arm. The injection site should be rotated each week.
Usage Rules: The drug is administered on any day of the week, regardless of meals. Before the first use, be sure to read the instructions for activating the multi-dose KwikPen.
Storage: Strictly in the refrigerator at 2°C–8°C. Do not freeze! After the first use, the pen can be stored at room temperature (up to 30°C) for no more than 21 days.

⛔ Medullary Thyroid Carcinoma: Personal or family history of this disease.
⛔ MEN 2: Multiple Endocrine Neoplasia syndrome type 2.
⛔ Pregnancy and Lactation: The drug is not recommended. When planning a pregnancy, use should be discontinued 1-2 months in advance.
⛔ Type 1 Diabetes: The drug is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.
Severe gastrointestinal diseases (e.g., severe gastroparesis).

Side effects most often appear at the beginning of treatment and diminish as the body adjusts:

🤢 GI Tract (very common): Nausea, diarrhea, vomiting, constipation, abdominal pain, heartburn.
🍽️ Metabolism: Significant decrease in appetite, risk of hypoglycemia (especially when combined with insulin or sulfonylureas).
🏃‍♂️ General: Weakness, increased fatigue, dizziness.
💉 Local: Redness or itching at the injection site.
⚠️ Rare but serious: Pancreatitis, gallbladder problems, kidney failure (against the background of severe dehydration during vomiting).

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 17.06.2026

Active ingredient

Tirzepatide